A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunityArticle Published on 2022-09-012023-07-09 Journal: Journal of medical virology [Category] COVID19(2023년), [키워드] BA.1 BA.2 omicron SARS-CoV-2 trimer Vaccine [DOI] 10.1002/jmv.27885
Classification of Omicron BA.1, BA.1.1, and BA.2 sublineages by TaqMan assay consistent with whole genome analysis dataArticle Published on 2022-09-012023-07-09 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), [키워드] BA.1 BA.2 omicron SARS-CoV-2 VOC. [DOI] 10.1016/j.ijid.2022.06.039 PMC 바로가기
Discrimination of SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 Using a High-Resolution Melting-Based Assay: a Pilot StudyArticle Published on 2022-08-312022-11-16 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome Analysis BA.1 BA.2 Care clinical sample clinical samples continuous monitoring coronavirus COVID-19 Delta determine develop discrimination domain High-resolution high-resolution melting identify L452R mutant Mutation Next-generation sequencing omicron Omicron variant Patient R408 Receptor-binding domain Region replacing RNA SARS-CoV-2 screening method Sensitivity and specificity severe disease significantly spike receptor-binding domain Spread T478K the SARS-CoV-2 time-consuming Transmission variant wild-type [DOI] 10.1128/spectrum.01367-22 PMC 바로가기
Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineagesSARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 및 BA.3 하위 계통의 항체 회피Article Published on 2022-08-102022-09-11 Journal: Cell Host & Microbe [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] antibody Antibody therapeutics antigenic approved BA.1 BA.1.1 BA.2 BA.3 BBIBP-CorV booster comparison dominant dose Efficacy highlighting homologous or heterologous IMPROVE inactivated individual lineages mAb mAbs monoclonal antibody MOST neutralization neutralization activity neutralization titer neutralization titers Neutralizing activity omicron profile pseudovirus reported SARS-CoV-2 sera side spike mutations Vaccine variant [DOI] 10.1016/j.chom.2022.05.001 PMC 바로가기 [Article Type] Article
Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2SARS-CoV-2 Omicron 하위 계통 BA.1, BA.1.1 및 BA.2의 중화Article Published on 2022-08-102022-09-11 Journal: Cell Host & Microbe [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] BA.1 BA.1.1 BA.2 booster doses Booster vaccine COVID-19 COVID-19 patient dose highlight Immune escape Immunity individuals lineages mRNA mRNA vaccine natural infection neutralization neutralized Neutralizing antibodies neutralizing antibody omicron overcome patient sera patients recent Recovered COVID-19 patients SARS-CoV-2 sensitivity sera Vaccine variant while [DOI] 10.1016/j.chom.2022.04.014 PMC 바로가기 [Article Type] Article
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies회복기 및 백신 혈청 및 단일 클론 항체에 의한 SARS-CoV-2 오미크론 하위 변이체 BA.1 및 BA.2의 제한된 중화Article Published on 2022-08-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 addition antibody BA.1 BA.2 BNT162b2 booster booster dose booster vaccination breakthrough infections Casirivimab Cell Complete convalescent convalescent sera Delta dominant dose education Efficacy elicited exhibited expressing Frankfurt Imdevimab Immunity in vitro study individual infection with SARS-CoV-2 Limited majority median monoclonal antibodies monoclonal antibody monoclonal antibody therapy Mutation neutralisation neutralise neutralising neutralizing capacity omicron Omicron variants reduced Region SARS-CoV-2 sera serum Sotrovimab specific resistance Spike protein supported tested the SARS-CoV-2 the spike protein therapy TMPRSS2 university vaccination Vaccine Vaccines variants variants of SARS-CoV-2 waning immunity [DOI] 10.1016/j.ebiom.2022.104158 PMC 바로가기 [Article Type] Article
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults이종 프라임-부스트 백신 접종 후 BNT162b2 부스터는 젊은 성인에서 SARS-CoV-2 Omicron BA.1에 대한 강력한 중화 항체 및 T 세포 반응성을 유도합니다Article Published on 2022-07-252022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] Adults analysed Antibody titer Antibody titers B.1 B.1.1.529.1 BA.1 BNT162b2 booster Cell cellular immunity ChAdOx1 ChAdOx1 nCoV-19 Cohort Course COVID-19 defined Delta dominant Effect effective elicited Epitopes Heterologous heterologous prime-boost humoral humoral and cellular immunity Humoral immunity immune immune protection immune responses Immunity individual induce initial interval maturation memory T memory T cell memory T cells nCoV neutralization titer neutralization titers neutralized Neutralizing activity neutralizing antibody omicron performed reactivity residual responses against resulting SARS-CoV-2 SARS-COV-2 infection spike epitope spike epitopes subsequent symptomatic SARS-CoV-2 infection T cell T cells the early SARS-CoV-2 vaccination vaccination interval. Vaccinations variant variants variants of concern VOCs [DOI] 10.3389/fimmu.2022.882918 PMC 바로가기 [Article Type] Article
High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1고용량 약물 스크리닝을 통해 SARS-CoV-2 Delta 및 Omicron/BA.1의 다양한 경로를 구체적으로 표적으로 하는 진입 억제제 식별 가능Article Published on 2022-07-012022-09-11 Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] COVID19(2023년), SARS, 변종, 신약개발, 유전자 메커니즘, [키워드] acute respiratory syndrome coronavirus Alpha antagonist antagonists applied BA.1 Beta Caco2 cells Cathepsin-L cell entry cells cellular entry chlorpromazine Combination Compound D614G Delta drug Drug repurposing Drug screening Entry inhibitor FDA-approved drugs G protein G protein coupled receptor antagonist G-protein help highest identify Infection route inhibit inhibitors lentiviral Lentiviral vector lentiviral vectors mechanism membrane fusion omicron pathway phenothiazine preference pseudotyped pseudovirus pseudoviruses receptor receptor antagonist Receptor binding receptors respiratory responsible resulting SARS-CoV-2 several variant several variants Severe acute respiratory syndrome specific inhibitors spike variant synergistic targets TMPRSS2 variant variant of concern viral entry VoC VOCs [DOI] 10.1016/j.biopha.2022.113104 PMC 바로가기 [Article Type] Article
Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021-February 2022SARS-CoV-2 오미크론 계통 BA.1 및 BA.2의 확산 분석 및 모델링, 프랑스, 2021년 9월-2022년 2월Article Published on 2022-07-012022-09-11 Journal: Emerging Infectious Diseases [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 analyzed BA.1 BA.2 breakthrough infections coronavirus coronavirus disease COVID-19 Critical delta variant Epidemiology France generate Genomics growth advantage hospital Lineage magnitude Mass screening measure median modeling Mutation omicron Omicron variant PCR PCR cycle respiratory infections Result SARS-CoV-2 SARS-CoV-2 variant screening test screening tests severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 threshold value vaccine-preventable diseases variant variants virulence viruses Whole-genome sequence zoonoses [DOI] 10.3201/eid2807.220033 PMC 바로가기 [Article Type] Article
Potent cross-reactive antibodies following Omicron breakthrough in vaccineesArticle Published on 2022-06-092023-07-09 Journal: Cell [Category] COVID19(2023년), [키워드] Antibody responses BA.1 BA.1.1 BA.2 COVID-19 Crystallography Immune escape neutralization omicron Receptor binding domain SARS-CoV-2 variants of concern [DOI] 10.1016/j.cell.2022.05.014 PMC 바로가기